Journal of Surgery Concepts & Practice >
Research progress on comprehensive treatment of locally advanced pancreatic cancer
QIAN Lihan, SHN Baiyong . Research progress on comprehensive treatment of locally advanced pancreatic cancer[J]. Journal of Surgery Concepts & Practice, 2020 , 25(05) : 442 -446 . DOI: 10.16139/j.1007-9610.2020.05.019
| [1] | Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. |
| [2] | Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic Adenocarcinoma, Version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(3):202-210. |
| [3] | Fogelman D, Sugar EA, Oliver G, et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma[J]. Cancer Chemother Pharmacol, 2015, 76(3):489-498. |
| [4] | Rahma OE, Duffy A, Liewehr DJ, et al. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials[J]. Ann Oncol, 2013, 24(8):1972-1979. |
| [5] | Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial[J]. J Clin Oncol, 1997, 15(6):2403-2413. |
| [6] | von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gem-citabine[J]. New Engl J Med, 2013, 369(18):1691-1703. |
| [7] | Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364(19):1817-1825. |
| [8] | Marthey L, Sa-Cunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort[J]. Ann Surg Oncol, 2015, 22(1):295-301. |
| [9] | Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis[J]. Lancet Oncol, 2016, 17(6):801-810. |
| [10] | Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial[J]. Lancet Oncol, 2013, 14(4):317-326. |
| [11] | Akahori T, Sho M, Yanagimoto H, et al. Phase Ⅱ study of the triple combination chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma[J]. Oncologist, 2019, 24(6):749-e224. |
| [12] | Sultana A, Tudur Smith C, Cunningham D, et al. Syste-matic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy[J]. Br J Cancer, 2007, 96(8):1183-1190. |
| [13] | Hammel P, Huguet F, van Laethem J, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib[J]. JAMA, 2016, 315(17):1844-1853. |
| [14] | Faris JE, Blaszkowsky LS, Mcdermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience[J]. Oncologist, 2013, 18(5):543-548. |
| [15] | Cattaneo GM, Passoni P, Longobardi B, et al. Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma[J]. Radiother Oncol, 2013, 108(1):66-71. |
| [16] | Prasad S, Cambridge L, Huguet F, et al. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer[J]. Pract Radiat Oncol, 2016, 6(2):78-85. |
| [17] | Fowler JF, Welsh JS, Howard SP. Loss of biological effect in prolonged fraction delivery[J]. Int J Radiat Oncol Biol Phys, 2004, 59(1):242-249. |
| [18] | Song Y, Yuan Z, Li F, et al. Analysis of clinical efficacy of CyberKnife® treatment for locally advanced pancreatic cancer[J]. Onco Targets Ther, 2015, 8:1427-1431. |
| [19] | Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer[J]. Nature, 2016, 531(7592):47-52. |
| [20] | Lee J, Jang KT, Ki CS, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma[J]. Cancer, 2007, 109(8):1561-1569. |
| [21] | Schultheis B, Reuter D, Ebert MP, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase Ⅱb study[J]. Ann Oncol, 2017, 28(10):2429-2435. |
| [22] | Waddell N, Pajic M, Patch A, et al. Whole genomes redefine the mutational landscape of pancreatic cancer[J]. Nature, 2015, 518(7540):495-501. |
| [23] | Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancrea-tic cancer: outcomes from the CONKO-003 trial[J]. J Clin Oncol, 2014, 32(23):2423-2429. |
| [24] | Watkins JA, Irshad S, Grigoriadis A, et al. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers[J]. Breast Cancer Res, 2014, 16(3):211. |
| [25] | Shroff RT, Hendifar A, Mcwilliams RR, et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation[J]. JCO Precis Oncol, 2018, 2018:10.1200/PO.17.00316. doi: 10.1200/PO.17.00316. |
| [26] | Hammel P, Kindler HL, Reni M, et al. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib[J]. Ann Oncol, 2019, 30(12):1959-1968. |
| [27] | Sahin IH, Askan G, Hu ZI, et al. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?[J]. Ann Oncol, 2017, 28(12):2950-2961. |
| [28] | Sahin IH, Lowery MA, Stadler ZK, et al. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches[J]. Expert Rev Gastroenterol Hepatol, 2016, 10(8):893-905. |
| [29] | Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin(CRS-207) boost vaccines for metastatic pancreatic cancer[J]. J Clin Oncol, 2015, 33(12):1325-1333. |
| [30] | Chung MJ, Park JY, Bang S, et al. Phase Ⅱ clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer[J]. Cancer Immunol Im-munother, 2014, 63(9):939-946. |
| [31] | Balaban EP, Mangu PB, Yee NS. Locally advanced unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary[J]. J Oncol Pract, 2017, 13(4):265-269. |
| [32] | 栗志磊, 范新奇, 包伟, 等. 局部进展期胰腺癌的诊治策略进展[J]. 中华肝胆外科杂志, 2018, 24(11):789-792. |
/
| 〈 |
|
〉 |
